Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus

Figure 1 Association of patient survival and achieving SVR. Five-year patient survival was superior in patients who achieved SVR (97% vs 82%, P = 0.001). Blue curve: Patients who did not achieve SVR; Red curve: Patients who achieved SVR.

Figure 2 Association of patient survival and baseline fibrosis. Five-year patient survival was superior in patients with low baseline fibrosis stage (P = 0.004). Blue curve: Patients with low baseline fibrosis stage; Red curve: Patients with moderate to advanced baseline fibrosis stage.